The latest reports from Wall Street say Allergan and Medicis, makers of Botox and Dysport, respectively, are posting increased revenues this quarter.
Analysts suggest that Botox and Dysport sales contributed significantly to that growth. Revenues for Dysport manufacturer Medicis last quarter increased 31 percent from the same period last year, according to CNN Money. “We are encouraged by the positive physician and patient response to DYSPORT” said CEO Jonah Shacknai.
Although other new products have given Medicis a boost, a very similar pattern is being seen with Botox manufacturer Allergan Inc. WSJ reports that a 3 percent increase in Botox sales helped Allergan’s third quarter profit rise 8.3 percent. New medical uses of Botox have the potential to increase Botox sales even further in the future, pending FDA approval of course.
Although there’s been a positive response to Dysport in Minneapolis, the brand awareness of Botox is still a major factor affecting sales, and that probably won’t change anytime soon.
